Patient Assistance Programs
SAFETY NET® 

The SAFETY NET® Foundation is a well-established patient assistance program that provides access to Amgen products for qualifying patients. Through a simple registration and enrollment process, patients who qualify for the SAFETY NET® Foundation can receive needed Amgen products through their enrolled provider.

Who is eligible? How can patients apply?

Certain uninsured or underinsured patients with limited financial resources are eligible for the SAFETY NET® Foundation. These patients must meet insurance and income eligibility criteria. Patients can apply for assistance through a sponsoring health care professional. To discuss enrollment, patients and providers may call the toll-free number.

When calling the SAFETY NET® Foundation, please be prepared with the following information:

Provider Information
  • Provider name
  • Name of contact person
  • Address of contact person
  • Telephone/fax numbers of contact person

Patient Information*
  • Written patient's writtenauthorization
  • Patient name
  • Social Security number
  • Duration of therapy
  • Patient's annual family income
  • Insurance information for all insurance plans in which the patient participates, including name of insurer, pending insurance coverage (and anticipated effective date), and any denied claim (with reason[s] for denial).
Download Patient Authorization Form (PDF, 45 Kb)
You need to have Adobe® Acrobat® installed to view PDF files. If you do not have Acrobat® Reader®, you can download it for free from Adobe® website.

Adobe® Reader® is a registered trademark of Adobe Systems, Inc.

*Before providing any patient-identifiable information (including name, social security number, address, ZIP Code, insurance policy number, or employer) to the SAFETY NET® Foundation staff, the provider must have the patient's written authorization to disclose such information for purposes of seeking reimbursement assistance or enrollment in the SAFETY NET® Foundation and provide such written authorization to the Reimbursement Connection®.

Amgen reserves the right to approve or deny any SAFETY NET® Foundation application or to modify or discontinue the program with respect to any patient or provider, or in its entirety, at any time. Amgen reserves the right to make an independent determination of eligibility in all cases.

Continue to Glossary.

Return to Information for Patients main page.

 

Neulasta® Indication and Important Product Safety Information

Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Product Safety Information

Splenic rupture (including fatal cases), acute respiratory distress syndrome, and sickle cell crises have been reported. Allergic reactions, including anaphylaxis, have also been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment.
In a placebo-controlled trial, bone pain occurred at a higher incidence in Neulasta®-treated patients as compared to placebo-treated patients (31% vs 26%). The most common adverse events reported in either placebo- or active-controlled trials were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain.

© 2007 Amgen All Rights Reserved. Prescribing Information for Neulasta®